What is the official website of High-Content Imaging | Molecular Devices ?

The official website of High-Content Imaging | Molecular Devices is https://www.moleculardevices.com/products/cellular-imaging-systems/high-content-imaging/imagexpress-hcs-ai.

What is High-Content Imaging | Molecular Devices's cybersecurity risk score?

High-Content Imaging | Molecular Devices has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has High-Content Imaging | Molecular Devices experienced?

According to Rankiteo, High-Content Imaging | Molecular Devices currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has High-Content Imaging | Molecular Devices been affected by any supply chain cyber incidents ?

According to Rankiteo, High-Content Imaging | Molecular Devices has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does High-Content Imaging | Molecular Devices have SOC 2 Type 1 certification ?

According to Rankiteo, High-Content Imaging | Molecular Devices is not certified under SOC 2 Type 1.

Does High-Content Imaging | Molecular Devices have SOC 2 Type 2 certification ?

According to Rankiteo, High-Content Imaging | Molecular Devices does not hold a SOC 2 Type 2 certification.

Does High-Content Imaging | Molecular Devices comply with GDPR ?

According to Rankiteo, High-Content Imaging | Molecular Devices is not listed as GDPR compliant.

Does High-Content Imaging | Molecular Devices have PCI DSS certification ?

According to Rankiteo, High-Content Imaging | Molecular Devices does not currently maintain PCI DSS compliance.

Does High-Content Imaging | Molecular Devices comply with HIPAA ?

According to Rankiteo, High-Content Imaging | Molecular Devices is not compliant with HIPAA regulations.

Does High-Content Imaging | Molecular Devices have ISO 27001 certification ?

According to Rankiteo,High-Content Imaging | Molecular Devices is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does High-Content Imaging | Molecular Devices operate in ?

High-Content Imaging | Molecular Devices operates primarily in the Biotechnology Research industry.

How many employees does High-Content Imaging | Molecular Devices have ?

High-Content Imaging | Molecular Devices employs approximately None employees people worldwide.

Does High-Content Imaging | Molecular Devices own any subsidiaries ?

High-Content Imaging | Molecular Devices presently has no subsidiaries across any sectors.

How many LinkedIn followers does High-Content Imaging | Molecular Devices have ?

High-Content Imaging | Molecular Devices's official LinkedIn profile has approximately 315 followers.

What is the NAICS classification code for High-Content Imaging | Molecular Devices ?

High-Content Imaging | Molecular Devices is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does High-Content Imaging | Molecular Devices have a Crunchbase profile ?

No, High-Content Imaging | Molecular Devices does not have a profile on Crunchbase.

Does High-Content Imaging | Molecular Devices have a LinkedIn profile ?

Yes, High-Content Imaging | Molecular Devices maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/high-content-imaging.

How many cybersecurity incidents has High-Content Imaging | Molecular Devices experienced ?

As of July 22, 2026, Rankiteo reports that High-Content Imaging | Molecular Devices has not experienced any cybersecurity incidents.

How many peer or competitor companies does High-Content Imaging | Molecular Devices have ?

High-Content Imaging | Molecular Devices has an estimated 4,730 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

HIMD

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

High-Content Imaging | Molecular Devices Vendor Cyber Rating & Cyber Score

moleculardevices.com

Add Your Compliance Badge

We empower researchers with cutting-edge AI-driven high-content screening solutions, delivering deeper insights into complex biological models. Our innovative ImageXpress® HCS.ai High-Content Screening System and IN Carta® Image Analysis Software streamline workflows for 2D and 3D assays, phenotypic screening, and live-cell imaging. Stay connected for expert insights, best practices, and success stories that advance discovery in academia, biotech, and pharma.

HIMD A.I CyberSecurity Scoring

Scoring History

HIMD

High-Content Imaging | Molecular Devices CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

HIMD Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for HIMD

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for High-Content Imaging | Molecular Devices in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for High-Content Imaging | Molecular Devices in 2026.

Incident Types HIMD vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for High-Content Imaging | Molecular Devices in 2026.

Incident History - HIMD (X = Date, Y = Severity)

Loading…

SUBSIDIARY

High-Content Imaging | Molecular Devices Subsidiaries

HIMD

Biotechnology Research

Website: https://www.moleculardevices.com/products/cellular-imaging-systems/high-content-imaging/imagexpress-hcs-ai

Company Size: 1,001-5,000 employees

Danaher CorporationMedical Equipment Manufacturing

Beckman Coulter DiagnosticsMedical Equipment Manufacturing

Beckman Coulter Dx North AmericaMedical Equipment Manufacturing

Beckman Coulter Dx BrasilFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx EEMEAتصنيع المعدات الطبية

Beckman Coulter Dx LATAMFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx Asia PacificMedical Equipment Manufacturing

한국벡크만쿨터의료장비 제조

CytivaBiotechnology Research

Pall Medical, part of CytivaMedical Equipment Manufacturing

Cytiva LATAMPesquisa biotecnológica

Pall CorporationManufacturing

Pall - Energy+Machinery Manufacturing

Aria FiltraEnvironmental Services

Pall - Food & BeverageFood and Beverage Services

Pall - AerospaceAviation and Aerospace Component Manufacturing

Pall - Energy+Machinery Manufacturing

Pall - MicroelectronicsAppliances, Electrical, and Electronics Manufacturing

CepheidBiotechnology Research

Leica MicrosystemsMedical Equipment Manufacturing

Leica Microsystems MedicalHospitals and Health Care

Leica BiosystemsMedical Device

Leica Biosystems EMEAMedical Equipment Manufacturing

Beckman Coulter Life SciencesBiotechnology Research

Beckman Coulter Life Sciences India, SWA, METAIBiotechnology Research

Beckman Coulter Life Sciences BrazilBiotechnology Research

Beckman Coulter Life Sciences TASK RegionBiotechnology Research

Beckman Coulter Life Sciences LATAMBiotechnology Research

Beckman Coulter Life Sciences - China生物技术研究

Beckman Coulter Life Sciences RussiaИсследования в сфере биотехнологий

SCIEXBiotechnology Research

SCIEX Food & Environmental Testing SolutionsBiotechnology Research

SCIEX Biopharma & Pharma SolutionsBiotechnology Research

SCIEX Omics SolutionsBiotechnology

SCIEX Forensic Testing SolutionsBiotechnology Research

SCIEX Service & SupportMedical Equipment Manufacturing

SCIEX Clinical ApplicationsMedical Equipment Manufacturing

SCIEX LatinoaméricaPesquisa biotecnológica

Integrated DNA TechnologiesBiotechnology Research

CRISPR genome editing by IDTBiotechnology Research

RadiometerMedical Equipment Manufacturing

AbcamBiotechnology Research

PhenomenexBiotechnology Research

Phenomenex - EMEABiotechnology

Danaher Life SciencesBiotechnology Research

Beckman Coulter Diagnostics EuropeMedical Equipment Manufacturing

AldevronBiotechnology Research

MammotomeMedical Equipment Manufacturing

Beckman Coulter Dx TurkeyTıbbi Ekipman İmalatı

Beckman Coulter Dx Eastern EuropeVýroba zdravotnických prostředků

Danaher India Development CenterIT System Custom Software Development

Beckman Coulter Dx China生物技术研究

Danaher DiagnosticsMedical Equipment Manufacturing

Beckman Coulter Dx India & SWAMedical Equipment Manufacturing

IDBSSoftware Development

PolarSoftware Development

GenedataBiotechnology Research

ジーンデータ（株）/ Genedata KKバイオテクノロジー研究

HemoCue ABMedical Equipment Manufacturing

Molecular DevicesBiotechnology Research

Clone Screening | Molecular DevicesBiotechnology Research

FLIPR Penta Drug Screening | Molecular DevicesBiotechnology Research

3D Biology | Molecular DevicesBiotechnology Research

High-Content Imaging & Analysis | Molecular DevicesBiotechnology Research

Loading…

High-Content Imaging | Molecular Devices Similar Companies

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Loading…

NEWS

High-Content Imaging | Molecular Devices CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 10, 2026 07:00 AM

Nearfield Instruments Unveils Sidewall Imaging for 3D Chip Metrology

Nearfield Instruments has announced the launch of its Sidewall Imaging Mode, a breakthrough measurement capability for its QUADRA...

Read Article

January 25, 2026 08:00 AM

What is a Cyber Security Job?

Cybersecurity is touted as having a zero unemployment rate. It is one of the fastest-growing and in-demand professions in the world today as...

Read Article

January 20, 2026 08:00 AM

ARPA-H funds digital twin tech for healthcare cybersecurity

Researchers at Northeastern University, working with several healthcare organizations and health tech companies, are developing...

Read Article

January 13, 2026 08:00 AM

Nebraska Innovation Studio names 2026 fellows

Nebraska Innovation Studio has named its 2026 Innovation Fellows: Bill Berzonsky, Jon Turkus, Dr. James Willcockson and Chris Wong.

Read Article

December 02, 2025 08:00 AM

Vendor notebook: Forging ahead on imaging and cybersecurity AI

Companies in November announced new efforts to fine-tune foundational models to advance radiology intelligence and implement baked-in...

Read Article

May 13, 2025 07:00 AM

The Silent Threat to Cybersecurity: Printers and MFPs in the Age of Digital Transformation

Cybersecurity-minded manufacturers are fighting back as imaging devices have become prime targets for hackers.

Read Article

March 27, 2025 07:00 AM

Growing Interest in Organoids: AI & Automated Solutions by Molecular Devices

The use of AI-driven tools, combined with automated systems, boosts organoid research by improving model reproducibility and scaling.

Read Article

March 20, 2025 07:00 AM

FBI issues alert on notorious ransomware group that targeted radiology practice

Medusa has hacked over 300 victims including SimonMed Imaging, hospitals, law firms and manufacturers, according to the federal...

Read Article

March 16, 2025 07:00 AM

Take action to prevent ransomware attacks

Healthcare is a critical, vulnerable and high-value target for cyber criminals. Spurred on by rampant system obsolescence and high-value...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…